Sandra Pérez Baos

Senior Associate at @2048vc • Early stage Biotech + Health VC • Former @nyugrossman postdoc & leadership team at @NucleateNY • Views my own.

[Sandra Pérez Baos @sperezbaos]

"𝘉𝘦 𝘤𝘶𝘳𝘪𝘰𝘶𝘴 𝘢𝘯𝘥 𝘮𝘢𝘬𝘦 𝘮𝘪𝘴𝘵𝘢𝘬𝘦𝘴, 𝘣𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘢𝘯𝘥 𝘥𝘰𝘯'𝘵 𝘨𝘪𝘷𝘦 𝘶𝘱" — Jane Goodall.

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

Take a break from the grind and the summer heat with a cold drink and good company!

@2048vc is hosting a mid-summer happy hour for founders, operators, and friends in New York.

📍 Hosted at @BrownRudnickLLP with @rhobusiness
📅 Wednesday, August 5
🕠 5:30–7:30pm

🎟️ RSVP: https://t.co/qIIX66NXsT

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

‼️ Deadline extended: 2 more days to apply to the @2048vc Pitch Competitions

Apply to pitch during @Techweek_:

Boston: 🧬 Biotech • May 27 | ⚙️ Deep Tech • May 28
New York: 🏥 Healthcare • June 2 | 🤖 Vertical AI • June 2

💰 $50K prize for each Biotech, Healthcare, and Vertical AI winner
💰 $100K prize for the Deep Tech winner (in partnership w/ @BoostVC)

Submit your application by SUNDAY April 26, 11:59 PM ET
🔗 Apply: https://t.co/P7daIUWayv
🔗 Learn more: https://t.co/wqswHOmETC

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

⏰ 3 days left to apply to the @2048vc Pitch Competitions

Don’t miss your chance to pitch during @Techweek_:

Boston
🧬 Biotech • May 27
⚙️ Deep Tech • May 28 (co-hosted with @BoostVC)

New York
🏥 Healthcare • June 2
🤖 Vertical AI • June 2

💰 $50K prize for each Biotech, Healthcare, and Vertical AI winner
💰 $100K prize for the Deep Tech winner (in partnership with Boost VC)

Apply by April 24: https://t.co/P7daIUWayv
Learn more: https://t.co/wqswHOmETC

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

📢 Reminder: Last week to apply for the @2048vc Pitch Competitions!

We’ll be hosting four pitch competitions in Boston and New York for @Techweek_:

Boston
🧬 Biotech - May 27
⚙️ Deep Tech - May 28 (co-hosted with @BoostVC)

New York
🏥 Healthcare - June 2
🤖 Vertical AI - June 2

💰 $50K prize for each Biotech, Healthcare, and Vertical AI winner
💰 $100K prize for the Deep Tech winner (in partnership with Boost VC)

Apply by April 24: https://t.co/P7daIUWayv
Learn more: https://t.co/wqswHOmETC

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

🚀 Ready to pitch your startup at @Techweek_?

We’re running four pitch competitions during Boston Tech Week and NY Tech Week:

Boston (May 27-28): Biotech, Deep Tech
NYC (June 2): Healthcare, Vertical AI

💰 $50K prize for each vertical winner
💰 $100K prize for the Deep Tech winner (w/ @BoostVC)

Apply by April 24: https://t.co/P7daIUWayv
Learn more: https://t.co/wqswHOmETC

[Gus Domel ⏻ @GusDomel]

So stoked to announce that we’re teaming up with our friends over at @2048vc to host a Deep Tech Pitch Competition on May 28 in Boston as part of Tech Week! Prize is a $100k investment from @BoostVC and 2048.

If you’re working on something hard and futuristic, we'd love to hear from you! We’re looking for founders obsessed with what they're building, and who are looking to change the world and make a Billion+ lives better. Applications close April 24, link below!

https://t.co/Q2krwmYJ7b

@thisiszann @alexiskold @emily_yu

[Sandra Pérez Baos @sperezbaos]

Reproductive healthspan will be one of the first domains where longevity science translates into clinical impact.

@IskoldLilly and I have captured this thinking in our latest @2048vc thesis. Read more below 👇

If you're building in the space, reach out: https://t.co/IGlVRLx7e7

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

Excited to share our latest @2048vc thesis series. Here you will find our Our Thesis on Reproductive Longevity.

If you are a founder in this space, please reach out!

This post was written by @IskoldLilly and @sperezbaos, with input from @JulieMarieWolf, and and originally appeared on the 2048 Ventures Blog: https://t.co/TfScQbOmbo

---

We believe reproductive healthspan will be one of the first domains where longevity science translates into clinical impact.

At 2048 Ventures, we invest in early-stage startups building defensibility through technology and proprietary data. Reproductive longevity is an area we’ve been increasingly excited about, where new biological breakthroughs and data-driven approaches are enabling a new generation of startups.

Longevity continues to be a defining theme of the future of healthcare and we believe reproductive healthspan will be one of the first domains where longevity science translates into clinical impact.

Reduced ovarian function is one of the earliest measurable signs of systemic aging. Despite decades of innovation in assisted reproduction, the biological drivers of fertility decline remain largely unaddressed. In our view, the most compelling technology targets the biological drivers of reproductive aging.

As our ability to measure and intervene in reproductive biology improves, care will increasingly shift from reactive treatment toward earlier measurement, prediction, and preventative intervention. We see a future where OB-GYNs routinely assess ovarian aging and fertility risk, forecast reproductive trajectories, and proactively intervene to extend reproductive healthspan.

Inevitabilities Shaping the Future of Reproductive Longevity

We see several inevitabilities:

1. Delayed parenthood will widen the gap between peak biological fertility and the timing of first birth. We are already seeing this demographic shift.
2. Reproductive biology will become a quantified system in which we can measure, predict, and intervene. Core drivers of reproductive aging (e.g., oocyte quality, ovarian function, endometrial receptivity) are becoming measurable at high resolution and over time. This data will enable prediction, personalization, and more precise intervention selection across the reproductive timeline.
3. A growing share of reproductive health will be technology-mediated. Assisted reproduction is broadly accepted socially and no longer confined to infertility. Technological intervention will become embedded in a growing proportion of pregnancies over time.

Bottlenecks and Opportunities Created

These inevitabilities highlight several gaps that still limit progress in the space:

- Proactive reproductive health monitoring is still lacking: Most fertility decisions are made with incomplete and reactive information. In addition, the timing of menopause remains largely unpredictable. There is an opportunity to develop longitudinal measurement tools and predictive models to map ovarian aging and enable earlier decisions around fertility preservation and proactive management of menopausal transition.
- Biological drivers of fertility remain poorly addressed: Despite widespread adoption of assisted reproduction, success rates remain far from guaranteed and decline sharply with age. There is an opportunity to develop interventions that 1) address core biological failure points (e.g. improve oocyte quality, boost implantation), and 2) build predictive decision support systems that can improve outcomes.
- Models of implantation biology are limited: The maternal-fetal interface and implantation involve complex interactions that are hard to reproduce in vitro, limiting both diagnostic and therapeutic innovation. There is an opportunity to develop models with human relevance that unlock proprietary datasets linked to clinical outcomes.

Where Reproductive Longevity Intersects with Our Core Theses:

We’re excited about this space because it sits at the intersection of the inevitabilities mentioned above, significant whitespace for innovation, and many of the core theses that anchor our investing at 2048 Ventures.

- Proprietary biological data and data defensibility: New biological models of ovarian aging, implantation, and the maternal-fetal interface can enable differentiated diagnostics and therapeutics, while generating proprietary, outcome-linked datasets.
- Compounding data and biobank moats: Reproductive medicine produces uniquely rich biological material—oocytes, embryos, endometrial samples—alongside longitudinal clinical data. Over time, this can evolve into proprietary biobanks and defensible data assets across fertility, maternal health, and longevity.
- Direct intersection with longevity science: Ovarian aging is one of the earliest measurable manifestations of systemic aging. Interventions that preserve or restore reproductive function provide a direct way to extend reproductive healthspan with clear biological endpoints.

Companies We Want to Meet:

We see three core categories of companies that represent the most compelling opportunities in this space:

- Diagnostics that guide biological intervention, specifically technologies that quantify egg quality, biological ovarian age, endometrial receptivity, and other reproductive biomarkers that enable earlier detection of reproductive decline. These tools will be used by clinicians to guide decisions around fertility preservation, IVF strategy, and therapeutic intervention.
- Early therapeutic interventions designed to extend reproductive healthspan by preserving ovarian reserve, improving oocyte quality or quantity, and modulating the biological drivers of ovarian aging. These can also be platforms that improve IVF outcomes by addressing implantation failure, embryo viability, and immune factors.
- Next-generation biological model infrastructure, ranging from engineered tissues to multimodal platforms, that enable faster testing and intervention development across ovarian aging and the maternal–fetal interface.

If you're a founder working in the space, we'd love to connect: https://t.co/xzo57Vsptj

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

Today, we’re thrilled to introduce our very first cohort of the @2048vc Ventures VC Fellows '26: a group of exceptional undergraduate and graduate students who are deeply embedded in startup ecosystems on their campuses and are excited about shaping the future of technology, startups, and venture.

https://t.co/ksFKwsNaoL

As 2048 Ventures VC Fellows, they’ll work directly alongside our investing team, identifying the next generation of category-defining startups and getting a front-row seat to diligence and beyond.

If you're a student building on their campuses, be sure to connect with our incredible fellows and apply via https://t.co/6JFEWFG0Zu 🚀

[Sandra Pérez Baos @sperezbaos]

If you are a builder and visionary looking for the highest conviction first-check investor, please reach out or re-share with your network!

[Sandra Pérez Baos @sperezbaos]

SO thrilled to share that we raised an oversubscribed $82M Fund III to lead pre-seed and seed rounds in Vertical AI, Deep Tech, Healthcare and Biotech startups in NYC and Boston.

https://t.co/7Dm64rLIYZ

[Sandra Pérez Baos @sperezbaos]

- We back exceptional, ultra-competitive, visionary founders.
- We lead pre-seed and seed rounds with $500K - $3M checks.
- We invest in Vertical AI, Deep Tech, Healthcare and Biotech.
- We invest primarily in NYC and Boston.
- We seek businesses with strong data moats.

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

Excited to share our latest @2048vc thesis series. Here you will find our Thesis on Drug Delivery.

If you are a founder in this space, please reach out!

This post was written by @sperezbaos, with input from @JulieMarieWolf and originally appeared on the 2048 Ventures Blog: https://t.co/fJALaMGWNy.

---

We’re interested in platforms that have delivery as their secret sauce, what we believe is the next major unlock in therapeutics.

At 2048 Ventures, we are obsessed with the future and look to invest in early-stage companies redefining industries through data and technology. Lately, we’ve been focused on drug delivery, a key infrastructure layer and a persistent bottleneck in the therapeutics space.

We now have an unprecedented ability to measure and model biology, from perturbation screens to single-cell and spatial omics. In parallel, toolkits like CRISPR and other modalities are expanding what we can do inside a cell. What hasn’t kept pace is our ability to deliver these tools precisely and safely to the right tissues and cells.

We believe delivery is the next major unlock in therapeutics and anticipate several inevitabilities:

1. Cell programming will increasingly happen in vivo, decreasing the need for ex vivo manipulation. We’re starting to see this trend with in vivo CAR-T.
2. The unprecedented resolution in mapping biological systems will inform targeting of highly specific cell subtypes and coordinated interventions that modulate several cell types and pathways in parallel.
3. We will gain access to durable and controllable interventions in chronic disease: therapies that work for years (or permanently), and can be switched on, off, or modulated as needed.

To truly unlock this future, delivery technologies must evolve into highly programmable platforms that are redosable, cell-specific, non-immunogenic, manufacturable at scale, and capable of efficient intracellular delivery across diverse payloads.

We’re interested in platforms that solve the delivery gap directly and have delivery as their secret sauce.

Bottlenecks and opportunities created

We have identified several bottlenecks and opportunities:

- Cross-species translation remains a major bottleneck as delivery vehicles that work in animal models often fail in humans. There is an opportunity to build human-first discovery engines early in development.
- Several delivery vehicles accumulate in the liver, limiting therapeutic efficacy and contributing to dose-limiting hepatotoxicity. There is an opportunity to engineer delivery systems to redirect tropism to tissues and cells of interest.
- Many delivery platforms elicit immune responses that prevent redosing or require immunosuppression. There is an opportunity to build stealth or immune-orthogonal vehicles with novel chemistries or immune cloaking strategies.
- Achieving controlled co-delivery of therapeutic cargoes often requires significant re-engineering of the delivery system. There is an opportunity to design truly modular scaffolds that accommodate a range of payloads and enable combination therapies in the same cell.

We’re proudly backing companies building against these challenges. @NionyxBio is directly tackling cross-species translation by engineering AAVs through a human-first discovery platform in kidney explants, enabling cell-level precision. @TwoStepTx is advancing a modular, highly specific integrin-binding peptide to enable selective delivery to virtually any solid tumor.

Manufacturability sets the ceiling for impact for delivery technologies

Manufacturing isn’t just a back-end problem, it’s part of the moat for delivery technologies. Biological innovation must be paired with a feasible, scalable, economically rational manufacturing strategy. Many delivery platforms fail not for lack of biological promise, but because they can’t scale.

Vector production is often the dominant driver of COGS. For example, for some AAVs, a 500 L batch can cost $3-7 million, translating to $1-2 million per dose in certain indications. High COGS, long lead times, inconsistent yields, and process complexity can easily derail otherwise compelling delivery platforms.

In addition, the economics really matter, especially when GMP-grade vector production can account for up to 50% of COGS and 60% of total manufacturing cost. Using expensive or low-yield vectors for a large, prevalent disease often breaks the model. Conversely, ultra-rare diseases can’t amortize fixed costs or benefit from scale.

The most successful delivery companies choose indications where batch size, pricing, and COGS naturally align. We believe owning a cost-efficient, reproducible process can be as valuable as owning the biology itself, and teams that treat manufacturing as core IP, not an afterthought, will be more defensible.

How delivery platforms unlock repeatable revenue

True platform value requires vertical validation, where the delivery system is proven through real therapeutic assets. In practice, this means demonstrating that the delivery mechanism works end-to-end in humans.

In our view, the most valuable delivery platforms are those where this vertical validation can be achieved with only minor adaptation, enabling rapid iteration across new assets once the core mechanism is proven. This creates asymmetric upside for platform developers: one validated targeting mechanism, many potential assets and partners.

Companies like ABL Bio (deals with Sanofi, GSK, Lilly), Vect-Horus (deals with Novo Nordisk, Ionis, Johnson & Johnson), Evox Therapeutics (deals with Takeda, Lilly) and many others exemplify how one delivery scaffold can anchor multiple pharma parternships, each applying the same core technology to different therapeutic cargos.

That said, these partnerships carry dependency risk. Ultimately, success often hinges on the partner’s therapeutic payload, clinical strategy, and indication choice. A platform with multiple partnerships sets up the company for maximum chance of success.

Startups we want to fund

We want to invest in startups developing:

- Novel modular and programmable delivery scaffolds that are highly specific, redosable, easy to manufacture, and compatible with a wide range of payloads and targeting ligands.
- Delivery systems capable of crossing the blood-brain barrier to achieve deep tissue penetration and specific targeting, ideally via systemic administration.
- High-resolution tissue and cell profiling tools that track delivery outcomes at single-cell or spatial resolution, enabling rational design of delivery technologies.
- Human tissue models for the discovery of delivery vehicles in physiologically relevant contexts, de-risking the lack of translatability from animal models to humans.
- Oral delivery systems for complex biologics that can withstand the gastrointestinal environment and enable non-invasive dosing routes.

In addition, we look for companies that design delivery platforms together with a manufacturable path: high yield, predictable quality, and economics that make sense for the chosen indication.

If you are a founder working in the space, we'd love to connect: https://t.co/xzo57VsXiR

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

🎉 We are thrilled to announce that Daniella Cohen (@daniellarcohen) has been promoted to Principal at @2048vc Ventures!

Daniella works tirelessly across all areas of the firm. She’s first to lend a hand when anyone needs help, investors and founders alike. From deep diligence to trialing MVPs, she applies her rigorous intellect and fantastic work ethic to everything that she does.

While Daniella’s dedication and creativity are reflected in our portfolio across the board, she’s played an especially integral role in building and working with the 2048 Ventures health portfolio.

Daniella first joined 2048 Ventures in 2021 as an intern and later that same year as an Associate. We are delighted to celebrate her continued growth at the firm!

Join us in congratulating Daniella! We look forward to seeing all she accomplishes as she steps into this new role.

📍 Connect with Daniella on LinkedIn: https://t.co/xr0kAGlzcJ, and follow her on X at @daniellarcohen

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

1. We’re so excited to launch 🚀 the @2048vc Fellowship, a program for the next generation of student 🎓 investors and builders in Boston!

👇

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

📢Introducing the 2048 Ventures Fellowship!

A program designed for the next generation of student investors and builders in Boston. 🚀🎓

👇

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

Today we are excited to welcome Edward Jin (@eddieejin) to 2048 Ventures as an Associate!

After reviewing hundreds of applications this year, Eddie stood out as one of the deepest thinkers we met. He has a clear way of reasoning through hard problems, a builder’s mindset, and technical judgement that’s rare.

Eddie will be based in our Boston office, and will spend time across our Deep Tech and Vertical AI practices.

Before joining 2048 Ventures, Eddie graduated from UC San Diego double majoring in Math-CS and Business Economics while investing into student-founded startups across the country at @DormRoomFund. He also, helped grow @DiscipulusVent in El Segundo, conducted research at Spero Ventures, and built internal tooling for Armada.

On a more personal note, Eddie is a perfect addition to our team: thoughtful, curious, and very easy to spend time with. He can nerd out on a surprisingly broad set of topics, loves playing poker, and is already scouting Boston for the best clam chowder.

We’re lucky to have Eddie on our team; please join us in welcoming him!

[Magdalena Tyrpien @Mtyrpien]

We couldn’t be more excited to have @2048vc lead our seed round at @NionyxBio. From the very first conversations with @alexiskold, @JulieMarieWolf and @sperezbaos, we clicked — fast-paced, brilliant, thoughtful, and deeply aligned on the urgency of building a new standard in kidney gene therapy.

Thrilled that @JulieMarieWolf is joining our board as we accelerate toward our next milestones. The partnership and conviction from the 2048 team means the world to us.

Onwards!

[Alex Iskold | 2048.vc @alexiskold]

@2048vc IS GROWING!

Come join @2048vc team in Boston as an Associate!

We are the highest conviction, early stage investor, writing lead checks for pre-seed and seed rounds across Vertical AI, Deep Tech, Health, and Bio.

We love being the first YES & we're incredibly privileged to work with founders at the earliest moments in their journeys.

Boston has become one of the most exciting places to do that: world-class schools, labs, and a growing community of ambitious founders. So we’re doubling down.

This is a rare hire for us, and we are confident this is an exceptional opportunity for someone looking to learn and broaden their super powers in VC.

You’ll be on the ground with @thisiszann sourcing, meeting founders, supporting on deals, and helping to build a preeminent pre/seed fund.

The sweet spot: 2–5 years of experience, prior venture/early-stage investing exposure, and a strong network.

You can be in already in Boston or want to relocate.

More information and application in the link below.

Please re-share this post with your network and help us spread the word!

👉 https://t.co/DfKrAXqAC5